{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:58:33Z","timestamp":1785333513746,"version":"3.55.0"},"reference-count":56,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In this Perspective, we summarize some of the most contentious issues surrounding diagnosis and treatment of myeloma. We outline how a fundamental clash of philosophies, cure versus control, may be at the heart of many of the controversies. From the very definition of the disease to risk stratification to the validity of current clinical trial endpoints, we highlight the major areas of debate and provide alternative viewpoints that have implications for trial design and interpretation, as well as clinical practice.<\/jats:p>","DOI":"10.1182\/blood-2011-06-297853","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T00:13:27Z","timestamp":1311725607000},"page":"3205-3211","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":118,"title":["Approach to the treatment of multiple myeloma: a clash of philosophies"],"prefix":"10.1182","volume":"118","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6sta","family":"Gahrton","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Huddinge, Stockholm, Sweden; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2020071611564396400_B1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma.","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2020071611564396400_B2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies.","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2020071611564396400_B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2020071611564396400_B4","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"6","key":"2020071611564396400_B5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020071611564396400_B6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma.","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clinic Proc"},{"issue":"7","key":"2020071611564396400_B7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1470-2045(11)70143-7","article-title":"Multiple myeloma and the road to personalised medicine.","volume":"12","author":"Russell","year":"2011","journal-title":"Lancet Oncol"},{"issue":"21","key":"2020071611564396400_B8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma [see comments].","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"24","key":"2020071611564396400_B9","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment].","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"2020071611564396400_B10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"13","key":"2020071611564396400_B11","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma.","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2020071611564396400_B12","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2020071611564396400_B13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"2020071611564396400_B14","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"26","key":"2020071611564396400_B15","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma [see comment].","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"9757","key":"2020071611564396400_B16","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line and ongoing treatment with zoledronic acid improves overall survival in patients with multiple myeloma: results of the MRC IX Randomised Controlled Trial.","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"2020071611564396400_B17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma.","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"issue":"22","key":"2020071611564396400_B18","first-page":"52","article-title":"Tandem autologous (ASCT)\/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): long term follow up of a prospective controlled trial by the EBMT [abstract].","volume":"114","author":"Gahrton","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"30","key":"2020071611564396400_B19","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020071611564396400_B20","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/leu.2009.173","article-title":"Proteasome inhibitors in the treatment of multiple myeloma.","volume":"23","author":"Shah","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"2020071611564396400_B21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JCO.1983.1.1.66","article-title":"Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results.","volume":"1","author":"Tannock","year":"1983","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020071611564396400_B22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2007.13.8156","article-title":"Reflections on medical oncology: 25 years of clinical trials. Where have we come and where are we going?","volume":"26","author":"Booth","year":"2008","journal-title":"J Clin Oncol"},{"issue":"31","key":"2020071611564396400_B23","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1200\/JCO.2008.17.6198","article-title":"Progress in cancer care: the hope, the hype, and the gap between reality and perception.","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020071611564396400_B24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2020071611564396400_B25","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"15","key":"2020071611564396400_B26","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma.","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2020071611564396400_B27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e3181c51cd4","article-title":"The importance of complete response in outcomes in myeloma.","volume":"15","author":"Nooka","year":"2009","journal-title":"Cancer J"},{"issue":"11","key":"2020071611564396400_B28","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/leu.2009.160","article-title":"The molecular characterization and clinical management of multiple myeloma in the post-genome era.","volume":"23","author":"Zhou","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"2020071611564396400_B29","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2020071611564396400_B30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences.","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020071611564396400_B31","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.","volume":"13","author":"Gahrton","year":"1995","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020071611564396400_B32","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents.","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020071611564396400_B33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"issue":"19","key":"2020071611564396400_B34","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood-2010-03-275800","article-title":"Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.","volume":"116","author":"Harousseau","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2020071611564396400_B35","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"23","key":"2020071611564396400_B36","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1158\/1078-0432.CCR-07-0527","article-title":"Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.","volume":"13","author":"Haessler","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2020071611564396400_B37","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2020071611564396400_B38","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients.","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2020071611564396400_B39","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"issue":"30","key":"2020071611564396400_B40","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III Trial.","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020071611564396400_B41","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2020071611564396400_B42","first-page":"613","article-title":"A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [abstract].","volume":"114","author":"Palumbo","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"2020071611564396400_B43","first-page":"622","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u2265 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract].","volume":"116","author":"Palumbo","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"2","key":"2020071611564396400_B44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma.","volume":"22","author":"Anderson","year":"2007","journal-title":"Leukemia"},{"issue":"21","key":"2020071611564396400_B45","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2020071611564396400_B46","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"2020071611564396400_B47","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"21","key":"2020071611564396400_B48","first-page":"310","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract].","volume":"116","author":"Attal","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"21","key":"2020071611564396400_B49","first-page":"37","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract].","volume":"116","author":"McCarthy","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"12","key":"2020071611564396400_B50","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.","volume":"16","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9758","key":"2020071611564396400_B51","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"2020071611564396400_B52","article-title":"Revlimid (lenalidomide): ongoing safety review.","volume-title":"Increased Risk of Developing New Malignancies","author":"Food and Drug Administration","year":"2011"},{"issue":"17","key":"2020071611564396400_B53","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.","volume":"29","author":"Korn","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020071611564396400_B54","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/83.10.1142","article-title":"Treatment of myeloma: cure vs control.","volume":"83","author":"Rajkumar","year":"2008","journal-title":"Mayo Clinic Proc"},{"issue":"12","key":"2020071611564396400_B55","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clinic Proc"},{"issue":"7246","key":"2020071611564396400_B56","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/459508a","article-title":"A change of strategy in the war on cancer.","volume":"459","author":"Gatenby","year":"2009","journal-title":"Nature"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/12\/3205\/1339853\/zh803811003205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/12\/3205\/1339853\/zh803811003205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T18:05:53Z","timestamp":1594922753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/12\/3205\/28783\/Approach-to-the-treatment-of-multiple-myeloma-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,22]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-06-297853","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,22]]}}}